Ignite Creation Date:
2024-05-06 @ 3:57 AM
Last Modification Date:
2024-10-26 @ 11:41 AM
Study NCT ID:
NCT02413827
Status:
TERMINATED
Last Update Posted:
2017-04-07
First Post:
2015-03-25
Brief Title:
A Study of Varlilumab Anti-CD27 and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
Sponsor:
Celldex Therapeutics
Organization:
Celldex Therapeutics
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-04
Start Date Type:
ACTUAL
Primary Completion Date:
2016-11-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2016-11-09
Completion Date Type:
ACTUAL
First Submit Date:
2015-03-25
First Submit QC Date:
April 9 2015
Study First Post Date:
2015-04-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
2017-04-06
Disp First Submit QC Date:
April 6 2017
Disp First Post Date:
2017-04-07
Disp First Post Date Type:
ACTUAL
Last Update Submit Date:
2017-04-06
Last Update Post Date:
2017-04-07
Last Update Post Date Type:
ACTUAL